These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7603600)

  • 1. Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA.
    Akeson P; Jonsson E; Haugen I; Holtås S
    Neuroradiology; 1995 Apr; 37(3):229-33. PubMed ID: 7603600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the safety of standard and triple dose gadodiamide injection in MR imaging of the central nervous system. A double-blind study.
    Svaland MG; Christensen T; Lundorf E
    Acta Radiol; 1994 Jul; 35(4):396-9. PubMed ID: 8011392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative studies of the tolerability of gadodiamide, dimeglumine gadopentetate and meglumine gadoterate in MRI tests of the central nervous system].
    Chanalet S; Masson B; Boyer L; Laffont J; Bruneton JN
    J Radiol; 1995 Jul; 76(7):417-21. PubMed ID: 7473375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system.
    Valk J; Algra PR; Hazenberg CJ; Slooff WB; Svaland MG
    Neuroradiology; 1993; 35(3):173-7. PubMed ID: 8459913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the clinical safety of gadodiamide injection, a new nonionic MRI contrast medium for the central nervous system: a European perspective.
    Aslanian V; Lemaignen H; Bunouf P; Svaland MG; Borseth A; Lundby B
    Neuroradiology; 1996 Aug; 38(6):537-41. PubMed ID: 8880714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system.
    Oudkerk M; Sijens PE; Van Beek EJ; Kuijpers TJ
    Invest Radiol; 1995 Feb; 30(2):75-8. PubMed ID: 7782190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadodiamide injection at 0.1 and 0.3 mmol/kg body weight: a phase III double-blind, parallel, randomised clinical investigation of known or suspected central nervous system lesions at 1.5 T.
    Demaerel P; Marchal G; Wilms G; Van Calenbergh F; De Greef D; Børseth A; Baert AL
    Neuroradiology; 1994 Jul; 36(5):355-9. PubMed ID: 7936174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the safety of the standard dose and a higher dose of gadodiamide injection for MR imaging of the central nervous system.
    Svaland MG; Lundby B; Kristoffersen DT
    J Magn Reson Imaging; 1994; 4(3):419-23. PubMed ID: 8061442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of the tolerability of gadodiamide, a new nonionic contrast agent in MRI of the central nervous system].
    Aslanian V; Lemaignen H; Bunouf P; Schiratti M; Lambrechts M; Lundby B; Borseth A; Svaland M
    J Radiol; 1995 Jul; 76(7):431-4. PubMed ID: 7473377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance and efficacy of Omniscan (gadodiamide injection) in MR imaging of the central nervous system.
    Ekholm S; Jonsson E; Sandvik L; Fagerlund M; Holtås S; Isberg B; Lindell D; Lindén B; Sjöberg S; Thuomas KA; Tollesson PO
    Acta Radiol; 1996 Mar; 37(2):223-8. PubMed ID: 8600967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with gadodiamide injection in magnetic resonance imaging of the central nervous system.
    Andrew E; Svaland M; Lundby B; Hugo F; LaFrance N
    Invest Radiol; 1994 Jun; 29 Suppl 2():S186-8. PubMed ID: 7928225
    [No Abstract]   [Full Text] [Related]  

  • 12. [Use of Omniscan (gadodiamide) in magnetic resonance studies of the central nervous system (results of a multicenter study)].
    Sinitsyn VE; Kornienko VN; Nikitin VG; Pronin IN; Ternovoĭ SK; Tiutin LA; Iakobson MG
    Vestn Rentgenol Radiol; 1995; (4):5-11. PubMed ID: 8571538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI in children given gadodiamide injection: safety and efficacy in CNS and body indications.
    Lundby B; Gordon P; Hugo F
    Eur J Radiol; 1996 Nov; 23(3):190-6. PubMed ID: 9003923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA).
    Brugières P; Gaston A; Degryse HR; Parizel PM; de Schepper AM; Berry I; Manelfe C; Le Bras F; Marsault C; Wichmann W
    Neuroradiology; 1994; 36(1):27-30. PubMed ID: 8107991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine.
    Sze G; Brant-Zawadzki M; Haughton VM; Maravilla KR; McNamara MT; Kumar AJ; Aisen AM; Dreisbach JN; Bradley WG; Weinreb JC
    Radiology; 1991 Dec; 181(3):693-9. PubMed ID: 1947084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA.
    Balériaux D; Matos C; De Greef D
    Neuroradiology; 1993; 35(7):490-4. PubMed ID: 8232870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS.
    Myhr G; Rinck PA; Børseth A
    Acta Radiol; 1992 Sep; 33(5):405-9. PubMed ID: 1389644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the magnetic resonance contrast agent gadodiamide in the central nervous system. Results of a multicenter trial.
    Sze G; Brant-Zawadzki M; McNamara MT; Haughton VM; Kumar AJ; Maravilla KR; Aisen AM; Dreisbach JN; Bradley WG; Weinreb JC
    Invest Radiol; 1993 Mar; 28 Suppl 1():S49-55. PubMed ID: 8486504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain metastases--comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging.
    Akeson P; Larsson EM; Kristoffersen DT; Jonsson E; Holtås S
    Acta Radiol; 1995 May; 36(3):300-6. PubMed ID: 7742127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.
    Reimer P; Rummeny EJ; Shamsi K; Balzer T; Daldrup HE; Tombach B; Hesse T; Berns T; Peters PE
    Radiology; 1996 Apr; 199(1):177-83. PubMed ID: 8633143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.